The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation
Open accessAbstract
Background and Purpose The results of a large prospective randomized trial have shown the efficacy of oral anticoagulation in the secondary prevention of major vascular events in patients with nonrheumatic atrial fibrillation (NRAF); less well established is the role of antiplatelet agents. The present study compared the effects of indobufen, a reversible inhibitor of platelet cyclooxygenase, with those of warfarin in this setting. Methods A total of 916 patients with NRAF and a recent (≤15 days) cerebral ischemic episode were admitted to this multicenter, randomized study, during which they were treated with either indobufen (100 or 200 mg BID) or warfarin (to obtain an international normalized ratio of 2.0 to 3.5) for 12 months. The two groups (462 on indobufen and 454 on warfarin) were well balanced in terms of their main baseline characteristics. The primary outcome of the study was the combined incidence of nonfatal stroke (including intracerebral bleeding), pulmonary or systemic embolism, nonfatal myocardial infarction, and vascular death. Results At the end of follow-up, the incidence of primary outcome events was 10.6% in the indobufen group (95% confidence interval, 7.7% to 13.5%) and 9.0% in the warfarin group (95% confidence interval, 6.3% to 11.8%), with no statistically significant difference between treatments. The frequency of noncerebral major bleeding complications was low: only four cases (0.9%) of gastrointestinal bleeding were observed, all of them in the warfarin group. Conclusions We conclude that, within the limitations of its design, this study may help the medical community in devising appropriate antithrombotic strategies for NRAF patients for whom oral anticoagulants are contraindicated or do not represent a feasible approach to treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: The fiamingham Study
Wolf, P. A., Dawber, T. R., Thomas, H. E., & Kannel, W. B. (1978) · Neurology · doi:10.1212/wnl.28.10.973 · Cited by 1,526
Cited by
Hart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Fuster, V., Rydén, L. E., Cannom, D. S., Crijns, H. J., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Le Heuzey, J.-Y., Kay, G. N., Lowe, J. E., et al. (2006) · Circulation · doi:10.1161/circulationaha.106.177292 · Cited by 2,805
Antithrombotic Therapy To Prevent Stroke in Patients with Atrial Fibrillation: A Meta-Analysis
Hart, R. G., Benavente, O., McBride, R., & Pearce, L. A. (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-131-7-199910050-00003 · Cited by 1,638
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Patrono, C., Coller, B., Dalen, J. E., Fitz Gerald, G. A., Fuster, V., Gent, M., Hirsh, J., & Roth, G. (2001) · Chest · doi:10.1378/chest.119.1_suppl.39s · Cited by 963
Metadata
- Authors
- Morocutti, C., Amabile, G., Fattapposta, F., Nicolosi, A., Matteoli, S., Trappolini, M., Cataldo, G., Milanesi, G., Lavezzari, M., Pamparana, F., & Coccheri, S.
- Venue
- Stroke
- Published
- 1997-05
- Volume
- 28
- Issue
- 5
- Pages
- 1015-1021
- ISSN
- 0039-2499 (ISSN-L)
- 1524-4628
- OpenAlex
- W2110392825
- Cited by
- 200
- References
- 1
- FWCI
- 6.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation. https://app.cochat.ai/papers/10.1161/01.str.28.5.1015
- The paper
- Morocutti, C., Amabile, G., Fattapposta, F., Nicolosi, A., Matteoli, S., Trappolini, M., Cataldo, G., Milanesi, G., Lavezzari, M., Pamparana, F., & Coccheri, S. (1997). Indobufen Versus Warfarin in the Secondary Prevention of Major Vascular Events in Nonrheumatic Atrial Fibrillation. Stroke. https://doi.org/10.1161/01.str.28.5.1015
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.